There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetes mellitus. It is hypothesized that these benefits are mediated by mechanisms other than glucose control. To address this, we performed a systematic review of data from preclinical studies examining the direct cardioprotective effects of SGLT2 inhibitors. Medline, EMBASE, CINAHL, and International Pharmaceutical Abstracts databases were searched for preclinical studies that examined the potential cardioprotective effects of SGLT2 inhibitors. Submission documents to the US Food and Drug Administration, European Medicines Agency, and Japanese Pharmaceutical and Medical Devices Agency for the registration of SGLT2 inhibitors were also reviewed. A total of 36 reports were included in the final analysis. The potential direct cardiovascular benefits of SGLT2 inhibitors include: augmentation of signal transducer and activator of transcription 3; inhibition of sodium hydrogen exchange; reduction of atherosclerosis; modulation of natriuretic peptides; vasodilation; modulation of sympathetic tone; and reduction of inflammation, oxidative stress, endoplasmic reticulum stress, and cardiac glucose uptake via down-regulation of SGLT1 expression. There are a number of mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits beyond glycaemic control.
Introduction
Recent years have witnessed the emergence of evidence from Phase III randomized clinical trials of the cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors among patients with Type 2 diabetes mellitus (T2DM). In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial, empagliflozin, in addition to standard care reduced the risk of the composite outcome of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke [hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.74-0.99; P = 0.04], cardiovascular death (HR 0.62, 95% CI 0.49-0.77; P < 0.001), and hospitalization for heart failure (HF) (HR 0.65, 95% CI 0.50-0.85; P = 0.002), compared with placebo. 1 In the Canagliflozin Cardiovascular Assessment Study (CANVAS) study, canagliflozin similarly reduced the risk of the composite outcome of cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke (HR 0.86, 95% CI 0.75-0.97; P = 0.02), compared with placebo. 2 The equivalent outcome study for dapagliflozin, Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), is ongoing, and expected to report in November 2018. 3, 4 Findings from randomized clinical trials concur with those of large observational studies. The Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL) Study reported that patients with T2DM newly treated with any SGLT2 inhibitor had lower risks of hospitalization for HF and all-cause death, 5 further supporting the notion of a class effect.
Beyond glucose control, the mechanisms underlying the cardioprotective effects of SGLT2 inhibitors among patients with T2DM remain unclear. Plausible protective mechanisms include lowering of blood pressure, improved renal haemodynamics, reduction in albuminuria, and amelioration of volume overload. 2 The exact subtypes of SGLT present in cardiovascular tissues, their potential roles in myocardial function and the effects of their blockade have been poorly defined. 4 Recent reviews and meta-analyses have examined this gap primarily using clinical data. 4, [6] [7] [8] Of note, these studies focused on the effects of SGLT2 inhibitors on the cardiovascular system, death and safety outcomes, and offer little insight about possible underlying direct mechanisms for the observed benefits. That is, mechanisms that are beyond what is clinically measurable (such as blood glucose). Therefore, we undertook a systematic review of data derived from preclinical studies to elucidate the mechanisms for the direct cardioprotective effects of SGLT2 inhibitors, under the assumption of a class effect.
Methods

Search methods
We performed a systematic review according to the recommendations in the PRISMA (Preferred Reporting Items for Systematic Review and Meta-analyses) statement. 9 
Inclusion/exclusion criteria
Reports were eligible for inclusion if data were drawn from mechanistic preclinical studies that examined the cardioprotective effects of SGLT2 inhibitors and reported in English. These included relevant review papers and regulatory submission reports that contained unpublished data.
Selection process
Two reviewers (K.L.C. and R.O.A.) checked all titles and abstracts for studies that potentially met the inclusion criteria. Subsequently, both reviewers independently reviewed and extracted data from eligible full text articles. Discrepancies were resolved by consensus with a third reviewer (D.L.).
Assessment of risk of bias in included studies
Two reviewers (K.L.C. and R. O.A.) independently assessed the risk of bias of included reports using the 'Animals in research: Reporting in vivo experiments' (ARRIVE) guidelines. Similar to the CONSORT Statement, the ARRIVE guidelines consist of a checklist of 20 items and is used to assess the quality of reporting in animal studies. 11, 12 We classified risk of bias as low, moderate or high if >15, 11-15, and < _10 of the checklist items, respectively, were met.
Results
Search results
A total of 2400 articles, of which 1202 were duplicates, were identified in the initial searches of the databases. Of the remaining 1211, 1173 did not meet the pre-specified inclusion criteria after review of their titles and/or abstracts. We reviewed the full text and/or abstracts of 38 articles and excluded a further 23 articles. Reasons for exclusion and PRISMA checklist are listed in Supplementary material online, S1 and S2, respectively. There were 21 additional articles identified through hand searching and submission reports. This resulted in 36 independent reports included in the final analysis. 4, Supplementary material online, S3 summarizes the risk of bias in the included studies. Overall, 12 studies were considered to have low risk of bias, 10 with moderate risk, and 14 with high risk. Figure 1 and Table 1 summarize the potential mechanisms for the direct cardioprotective effects of SGLT2 inhibitors from the included studies. Supplementary material online, S4 provides a detailed summary of study designs and findings of the included studies.
Cardiac function
Demarco et al. 17 evaluated whether or not empagliflozin improves dysglycaemia, proteinuria, aortic stiffness, and diastolic dysfunction in obese/ diabetic female db/db mice (a spontaneous Type 2 diabetes model). In this study, empagliflozin (10 mg/kg/day for 5 weeks) improved septal wall motion, flow propagation velocity, left ventricular filling pressure, isovolumic relaxation time, and myocardial performance. Pulse wave velocity was elevated in the control but not the treatment group. The same investigators also showed that empagliflozin reduced proteinuria and renal resistivity index, 38 potentially reducing haemodynamic stresses via the cardiorenal axis. Lin et al. 31 showed that cardiac interstitial fibrosis, coronary arterial remodelling, vascular endothelial dysfunction, cardiac interstitial macrophage infiltration, and cardiac superoxide levels in mice were significantly attenuated following 10 weeks of empagliflozin treatment (normal chow diet containing 0.03% empagliflozin) using db/db mice. Similar findings were reported by Lee et al. 30 using a post-infarction model of non-diabetic male Wistar rats. Post-infarction was associated with increased levels of superoxide and nitrotyrosine, which were attenuated by both dapagliflozin and phlorizin (a non-specific SGLT1/SGLT2 inhibitor), administered 24 h after infarction for 4 weeks. SGLT2 inhibitors significantly increased myocardial interleukin (IL)-10 levels and the degree of M2 macrophage infiltration via increased signal transducer and activator of transcription 3 (STAT3) activity and STAT3 nuclear translocation. At Day 28 after infarction, SGLT2 inhibitors were associated with attenuated myofibroblast infiltration and cardiac fibrosis. Although phlorizin decreased myofibroblast infiltration, the capacity of dapagliflozin to attenuate myofibroblast infiltration was significantly greater than phlorizin. The effects of SGLT2 inhibitors on cardiac fibrosis were nullified by adding S3I-201(a STAT3 inhibitor). Furthermore, the effects of dapagliflozin on STAT3 activity and myocardial IL-10 levels could be reversed by 3-morpholinosydnonimine, a peroxynitrite generator. Taken together, these observations suggest a novel mechanism of SGLT2 inhibitor-mediated M2 polarization through a reactive oxygen and nitrogen species (RONS)-dependent STAT3-mediated pathway. Also, selective SGLT2 inhibitor, dapagliflozin, is more effective than phlorizin in attenuating myofibroblast infiltration during post-infarction remodelling. SGLT2 inhibitor remodelling effects were also reported by Joubert et al., 27 who showed that dapagliflozin significantly reduced O-GlcNAcylated FOXO1 levels in seipin knockout mice (a lipodystrophic model) compared with non-treated group, which subsequently prevented the development of hypertrophic cardiomyopathy. Dapagliflozin (1 mg/ kg/day for 8 weeks) attenuated the development of fibrosis and remodelling and deterioration of left ventricular function in BTBR mice, and these effects were shown to be adenosine monophosphate-activated protein kinase (AMPK)-dependent and SGLT1-independent. 46 
Intracellular ion handling
Increased intracellular concentration of sodium and up-regulated sodium hydrogen exchange (NHE) activity are associated with HF and diabetes. 48 By using freshly isolated ventricular cardiomyocytes of mice and a molecular docking approach, Uthman et al. 44, 45 demonstrated that empagliflozin, dapagliflozin, and canagliflozin directly inhibit cardiac NHE flux and reduce intracellular concentration of sodium, potentially by binding with the Na þ -binding site of NHE-1. The authors also showed that empagliflozin and canagliflozin, but not dapagliflozin, induced coronary vasodilation in the heart. Hamouda et al. 24 demonstrated that dapagliflozin reduced the amplitude of ventricular myocytes shortening, calcium transient, and L-type calcium current, suggesting that alteration in the mechanism(s) of calcium transport may partly explain the negative inotropic effects of SGLT2 inhibitors. However, Hamouda et al. did not directly compare the effects of SGLT2 inhibitors and beta-blockers on the sympathetic nervous system.
Atherosclerosis
Repetitive post-prandial fluctuation in glucose concentration evokes monocytes adhesion to endothelium cells. 14 Macrophage scavenger receptors CD36 and lectin-like ox-low-density lipoprotein receptor-1 (Lox-1) scavenge oxidized-low density lipoproteins (ox-LDL) leading to foam cell formation and atherosclerosis. 40 Treatment with phlorizin suppressed adhesion of monocytes on aortic endothelium, while both dapagliflozin and ipragliflozin attenuated the up-regulation of gene expression Figure 1 Mechanisms underlying cardiovascular benefits of the SGLT2 inhibitors. • Oral empagliflozin (10 mg/kg/day) for 5 weeks
•
Improvements in all outcomes
Lin et al. • n = 7-10 • Murine heart perfused with phlorizin (10 -4 mol/L) in ex vivo experiments
•
Samples of human heart tissues were also used in the immunohistochemistry experiments
• SGLT1 was highly expressed in both human autopsied hearts and murine perfused hearts • Prevented the development of blood pressure elevation with normalization of its circadian rhythm to a dipper profile, which was associated with increased urinary sodium excretion
All included studies have control group. Full description of study designs and findings are summarized in Supplementary material online, S4. AA, Aristolochic acid; ACR, albumin/creatinine ratio; BP, blood pressure; CAECs, coronary artery endothelial cells; CASMCs, coronary artery smooth muscle cells; GFR, glomerular filtration rate; LA, locomotor activity; n, number of animals per group; NHE, Sodium hydrogen exchange; Nrf2, nuclear factor erythroid 2-related factor 2; PAECs, pulmonary artery endothelial cells; PASMCs, pulmonary artery smooth muscle cells; SBP, systolic blood pressure; SKO, seipin knockout; WT, wild-type. 25 further demonstrated that empagliflozin mitigated the atherosclerotic process by decreasing inflammation and insulin resistance. The same study also reported that insulin resistance and circulating concentrations of TNF-alpha, IL-6, monocyte chemoattractant protein-1 (MCP-1), serum amyloid A, and urinary microalbumin decreased after empagliflozin treatment, and this significantly correlated with plaque size. Furthermore, empagliflozin reduced weight, fat mass, lipid droplets in the liver and fat cell size by increasing adiponectin levels. 25 Adinopectin reduces expression of adhesion molecules in endothelial cells and decreases cytokine production from macrophages by inhibition of NF-j B signalling through cAMP-dependent pathway; suppression of foam cell transformation, proliferation and migration of smooth muscle cells induced by platelet-derived growth factor and C-reactive protein. 49 
Modulation of neurohormones
By employing a validated zebrafish model in HF, Shi et al. 37 showed that empagliflozin modulates brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) signalling pathways, and subsequently attenuated cardiac remodelling and death. In this study, empagliflozin significantly reduced the morphological and functional cardiac changes induced by aristolochic acid (AA), dampened AA-enhanced expression of prohypertrophic markers BNP and ANP, and reduced embryonic mortality.
Blood pressure
Canagliflozin's blood pressure lowering effect was reported by Abu Seif et al. 13 Using a model of streptozotocin-induced diabetic rats, canagliflozin (10 mg/kg body weight for 28 days) significantly reduced mean blood pressure by 5.2% after 28 days of treatment. Canagliflozin (30 mgÁ10 mL -1
Ákg body weight -1 via oral gavage daily for 4 weeks) augmented sodium nitroprusside-dependent relaxation in coronary arteries in diabetic mice through induction of membrane hyperpolarization in smooth muscle cells, mediated by activation of potassium channels, but not in papaverine-induced model. 26 In contrast, canagliflozin (0.3 mg/mL in drinking water for 16 weeks) was not found to significantly reduce systolic blood pressure, tubular oxidative stress, expression of angiotensinogen and nuclear factor erythroid 2-related factor 2 in renal proximal tubules, urinary angiotensinogen, and angiotensin II levels compared with controls in diabetic Akita mice models. 16 
Sympathetic nervous system
Using a streptozotocin-induced diabetic C57BL6 mice model, canagliflozin (10 mg/kg/day for 4 weeks) reduced heart size, left ventricular dilatation, and circulating glucagon concentration. 28 Glucagon exerts positive inotropic and chronotropic effects in the heart. 50 Therefore, SGLT2 inhibition may potentially lower sympathetic activation by reducing glucagon levels. 19 
Oxidative stress
Increased formation of advanced glycation end products (AGE) and their signalling via specific receptors (RAGE), activate sources of reactive oxygen species (ROS) leading to vascular dysfunction and end organ damage. [51] [52] [53] Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function and reduced oxidative stress in aortic vessels and in blood of diabetic rats. 32 The same study also demonstrated that empagliflozin reversed the pro-inflammatory phenotype and glucotoxicity (AGE/RAGE signalling) in diabetic animals.
Inflammation
Ye et al. 46 found that dapagliflozin (1 mg/kg/day for 8 weeks) attenuated the activation of the nucleotide binding oligomerization domain (NOD)-like receptor 3 (NLRP3) inflammasome and up-regulation of C-reactive protein.
The anti-inflammatory effect was AMPK-dependent and SGLT1-independent.
Apoptosis
Excessive endoplasmic reticulum stress (ERS) can lead to apoptosis, a pathophysiological process contributing to dilated and ischaemic cardiomyopathy. 54 In two tested doses of 10 mg/kg/day and 30 mg/kg/day, empagliflozin was shown to improve mean pressure-volume relationships and ventricular contractility, and to also alleviate histopathologic changes and ERS-induced apoptosis of cardiomyocytes by downregulating downstream proteins of the apoptosis pathways (CHOP, Caspase-12, GRP-78, and TRAF2) in streptozotocin-induced diabetic cardiomyopathy rat model. 47 
SGLT1
SGLT1 expression has been shown to be significantly up-regulated in ischaemia and hypertrophy, in association with increased phosphorylation in activating domains of the intracellular second messengers AMPK, extracellular-signal regulated kinase 1 and 2 (ERK-1/2), and mammalian target of rapamycin (mTOR). 18 Increased SGLT1 expression in turn mediates increased cardiac glucose uptake. 15 
Circadian rhythm
Luseogliflozin (10 mg/kg/day) and empagliflozin (10 mg/kg/day) were both shown to normalize circadian rhythm of blood pressure restoring physiological nocturnal dip in blood pressure, which was associated with increased urinary sodium excretion. 35 ,36,39
Discussion
The findings from our systematic review indicate that SGLT2 inhibitors may exert direct cardiovascular benefits by attenuating myocardial remodelling and atherosclerosis. Potential mechanisms include augmentation of STAT3 activity, anti-inflammatory activity, anti-fibrosis activity, reduction of oxidative stress, modulation of neurohormones, inhibition of NHE flux, and promotion of vascular relaxation. The timing of cardiovascular benefits observed in the EMPA-REG OUTCOME, CANVAS, and CVD-REAL studies, 6, 48 suggests that the cardioprotective effects of SGLT2 inhibitors are mediated by other mechanisms beyond glycaemic control. Contemporary clinical data have consistently showed that patients receiving SGLT2 inhibitors also experience reduction in blood pressure, arterial stiffness, weight loss, urinary albumin excretion, uric acid levels, and favourable effects on the lipid parameters. 55, 56 However, it is not clear whether these ancillary effects confer direct mortality benefits as observed in the trials. Our review suggests that the favourable effects of SGLT2 inhibitors are likely also to be driven by the inhibitory effects on the NHE activity and activation of the STAT3 pathway. The activity of NHE is markedly increased in HF. 57 Such an increase would enhance the intracellular concentration of calcium and activation of Ca 2þ /calmodulin-dependent protein kinase (CaMK)II-histone deacetylase pathway, leading to cardiac hypertrophy and HF. 58 As discussed earlier, attenuation of the STAT3-mediated pathway leads to cardiac interstitial fibrosis, coronary arterial remodelling, vascular endothelial dysfunction, cardiac interstitial macrophage infiltration, and cardiac superoxide levels. The effect of SGLT2 inhibitors concurrently on both pathways may represent a novel mechanism to attenuate ongoing maladaptive remodelling processes. Interestingly, spironolactone was shown to inhibit NHE in the aorta of mineralocorticoid-induced hypertensive rats. 59 In addition, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists all ameliorate cardiac remodelling that stems from apoptosis, fibrosis, and hypertrophy. 60 During atherogenesis, endothelial dysfunction, monocyte adhesion, oxidative stress, foam cell formation, vascular smooth muscle proliferation, collagen deposition, and platelet activation occur. 61 Ox-LDL, which has an important role in atherosclerotic plaque formation, facilitates monocytes adhesion to the endothelial lining, and formation of foam cells. 62, 63 Ox-LDL is taken up by cells in the arterial wall through scavenger receptors, mainly CD36 and Lox- 1. 62,63 The expression of Lox-1 is up-regulated within atherosclerotic plaque and surrounding tissues. 62 Lox-1-mediated ROS generation induces mitochondrial DNA damage, vascular smooth muscle cell proliferation, neointima formation, and enhances expression of the NLRP3 inflammasome. 62 Activation of the NLRP3 inflammasome, potentially through the c-Jun N-terminal kinase (JNK) pathway, results in increased production of inflammatory cytokines and apoptosis in macrophages. 64 Inhibition of Lox-1 decreases lipopolysaccharide-induced cellular and mitochondrial ROS generation and all subsequent downstream signals, including autophagy and NLRP3 activation. 62 Likewise, absence of CD36 has been shown to be protective against atherosclerosis. 65 The blood pressure lowering effects of SGLT2 inhibitors observed in pre-clinical studies were consistent with those found in human studies. 1, 2 While canagliflozin was shown to attenuate glucagon levels in animal studies 28 , empagliflozin was associated with hyperglucagonaemia in one human study (n = 66) conducted over 4 weeks. 66 Notably, the results from these two studies are at odds and need to be interpreted cautiously, mindful of differences between humans and animals. Of note, the 'fuel shift' hypothesis has garnered some interest in view of altered fatty acid oxidation and impaired glucose uptake/oxidation in the heart among patients with T2DM, increasing their risk of cardiac dysfunction and HF. 67 The glycosuria induced by SGLT2 inhibitors leads to mild and persistent hyperketonaemia due to increased production of hepatic ketones. The increased concentration of ketones confers a more efficient fuel source for the heart, and translates into increased cardiac efficiency and function. 67, 68 However, robust data to support this hypothesis are still lacking. Further research could examine the cardioprotective effects of SGLT2 inhibitors in non-diabetic animal models. From the clinical standpoint, the efficacy of SGLT2 inhibitors in reducing cardiovascular events in patients with pre-existing cardiovascular disease but without T2DM, patients with T2DM but without cardiovascular disease and patients with both T2DM and HF should be investigated. More data are also needed with regards to the effects of SGLT2 inhibitors on temporal changes in cardiac structure and function (assessed via biomarkers, echocardiography, and coronary flow reserve 
Study limitations
Our analysis is subject to several limitations that warrant discussion. The studies included in this analysis were small and heterogeneous, using different species, strains, disease models, routes of administration, dosages and outcome measures. Nevertheless, one overarching and consistent finding is beneficial effects on many aspects of cardiovascular pathophysiology. Secondly, the results from animal studies may not be directly extrapolated to human subjects, although the animal models used were all at least typical for cardiovascular mechanistic studies. Thirdly, as with most systematic reviews, our review may have been subject to publication bias. We had sought to identify all studies, even those that were unpublished, but may not have captured all relevant studies. We acknowledge that publications are usually biased towards positive findings, and hence there may have been an 'over-calling' of the benefits of SGLT2 inhibitors on cardiovascular physiology. Lastly, further bias may have arisen from our limitation of component studies to English, although the extent of this bias, if present, would likely have been small.
Conclusion
SGLT2 inhibitors are likely to exert direct cardioprotective effects through inhibitory effects on the STAT3 pathway, NHE activity, atherosclerosis, modulation of neurohormones, promotion of vasodilation, inflammation, as well as oxidative stress.
